TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET 75
1.4 CURRENCY AND PRICING 77
1.5 LIMITATIONS 77
1.6 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
2.1 MARKETS COVERED 81
2.2 GEOGRAPHICAL SCOPE 82
2.3 YEARS CONSIDERED FOR THE STUDY 83
2.4 DBMR TRIPOD DATA VALIDATION MODEL 84
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
2.6 MULTIVARIATE MODELLING 88
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 88
2.8 MARKET APPLICATION COVERAGE GRID 89
2.9 DBMR MARKET POSITION GRID 90
2.10 VENDOR SHARE ANALYSIS 91
2.11 SECONDARY SOURCES 92
2.12 ASSUMPTIONS 92
3 EXECUTIVE SUMMARY 93
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTER'S 5 FORCES 97
5 INDUSTRY INSIGHTS 98
6 REGULATORY FRAMEWORK 100
6.1 REGULATORY SCENARIO BY U.S. FDA 100
6.2 REGULATORY SCENARIO IN U.S. 100
6.3 REGULATORY SCENARIO IN EUROPE 101
6.4 REGULATORY SCENARIO IN CANADA 101
6.5 REGULATORY SCENARIO IN AUSTRALIA 101
7 MARKET OVERVIEW 102
7.1 DRIVERS 104
7.1.1 RISING CASES OF COLORECTAL CANCER ASIA PACIFICLY 104
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 104
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 105
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 105
7.2 RESTRAINTS 105
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 105
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 106
7.3 OPPORTUNITIES 106
7.3.1 INCREASE IN SCREENING PROCEDURES 106
7.3.2 RISING TECHNICAL ADVANCEMENTS 107
7.3.3 STRATEGIC INITIATIVES 107
7.4 CHALLENGES 108
7.4.1 LACK OF SKILLED PROFESSIONALS 108
7.4.2 LOW EFFICIENCY 108
8 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 109
8.1 OVERVIEW 110
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 113
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 113
8.4 IMMUNO-FOB ELISA TEST KITS 114
8.5 GUAIAC FOB STOOL TEST 115
8.5.1 KITS 116
8.5.1.1 GUAIAC SLIDES 116
8.5.1.1.1 25 PACKAGE 116
8.5.1.1.2 20 PACKAGE 116
8.5.1.1.3 OTHERS 116
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 117
8.5.1.2.1 SENSITIVITY IS 50NG/ML 117
8.5.1.2.1.1 25 PACKAGE 117
8.5.1.2.1.2 20 PACKAGE 117
8.5.1.2.1.3 OTHERS 118
8.5.1.2.2 SENSITIVITY IS 75NG/ML 118
8.5.1.2.2.1 25 PACKAGE 118
8.5.1.2.2.2 20 PACKAGE 118
8.5.1.2.2.3 OTHERS 118
8.5.1.2.3 OTHERS 118
8.5.1.3 OTHERS 119
8.5.2 REAGENTS 119
8.5.2.1 HYDROGEN PEROXIDE 119
8.5.2.2 OTHERS 119
8.6 FLUSHABLE REAGENT PAD OR TISSUE 119
8.7 OTHERS 120
9 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 121
9.1 OVERVIEW 122
9.2 COLORECTAL CANCER SCREENING 125
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 126
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 126
9.2.3 IMMUNO-FOB ELISA TEST KITS 126
9.2.4 GUAIAC FOB STOOL TEST 126
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 126
9.2.6 OTHERS 126
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 126
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 127
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 127
9.3.3 IMMUNO-FOB ELISA TEST KITS 127
9.3.4 GUAIAC FOB STOOL TEST 128
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 128
9.3.6 OTHERS 128
9.4 POLYPS 128
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 129
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 129
9.4.3 IMMUNO-FOB ELISA TEST KITS 129
9.4.4 GUAIAC FOB STOOL TEST 129
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 129
9.4.6 OTHERS 129
9.5 DIVERTICULOSIS 130
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
9.5.3 IMMUNO-FOB ELISA TEST KITS 131
9.5.4 GUAIAC FOB STOOL TEST 131
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 131
9.5.6 OTHERS 131
9.6 ULCERS 131
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 132
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 132
9.6.3 IMMUNO-FOB ELISA TEST KITS 132
9.6.4 GUAIAC FOB STOOL TEST 133
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 133
9.6.6 OTHERS 133
9.7 HAEMORRHOIDS 133
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 134
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 134
9.7.3 IMMUNO-FOB ELISA TEST KITS 134
9.7.4 GUAIAC FOB STOOL TEST 134
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 134
9.7.6 OTHERS 134
9.8 COLITIS 135
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
9.8.3 IMMUNO-FOB ELISA TEST KITS 136
9.8.4 GUAIAC FOB STOOL TEST 136
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 136
9.8.6 OTHERS 136
9.9 ANEMIA 136
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 137
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 137
9.9.3 IMMUNO-FOB ELISA TEST KITS 137
9.9.4 GUAIAC FOB STOOL TEST 138
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 138
9.9.6 OTHERS 138
9.10 OTHERS 138
10 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET, BY END USER 139
10.1 OVERVIEW 140
10.2 DIAGNOSTIC LABORATORIES 143
10.3 HOSPITALS 143
10.4 SPECIALITY CLINICS 144
10.5 OTHERS 145
11 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 146
11.1 OVERVIEW 147
11.2 DIRECT TENDER 150
11.3 RETAIL SALE 150
11.4 E-COMMERCE 151
11.5 OTHERS 152
12 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET, BY REGION 153
12.1 ASIA-PACIFIC 154
12.1.1 CHINA 167
12.1.2 JAPAN 175
12.1.3 INDIA 183
12.1.4 AUSTRALIA 191
12.1.5 SOUTH KOREA 199
12.1.6 THAILAND 208
12.1.7 SINGAPORE 216
12.1.8 INDONESIA 224
12.1.9 MALAYSIA 233
12.1.10 PHILIPPINES 242
12.1.11 REST OF ASIA-PACIFIC 251
13 ASIA PACIFIC FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 252
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 252
14 SWOT ANALYSIS 253
15 COMPANY PROFILE 254
15.1 QUIDEL CORPORATION 254
15.1.1 COMPANY SNAPSHOT 254
15.1.2 REVENUE ANALYSIS 254
15.1.3 COMPANY SHARE ANALYSIS 255
15.1.4 PRODUCT PORTFOLIO 255
15.1.5 RECENT DEVELOPMENT 255
15.2 WONDFO. 256
15.2.1 COMPANY SNAPSHOT 256
15.2.2 COMPANY SHARE ANALYSIS 256
15.2.3 PRODUCT PORTFOLIO 257
15.2.4 RECENT DEVELOPMENT 257
15.3 SIEMENS HEALTHCARE GMBH 258
15.3.1 COMPANY SNAPSHOT 258
15.3.2 REVENUE ANALYSIS 258
15.3.3 COMPANY SHARE ANALYSIS 259
15.3.4 RODUCT PORTFOLIO 259
15.3.5 RECENT DEVELOPMENT 259
15.4 EIKEN CHEMICAL CO., LTD. 260
15.4.1 COMPANY SNAPSHOT 260
15.4.2 REVENUE ANALYSIS 260
15.4.3 COMPANY SHARE ANALYSIS 261
15.4.4 PRODUCT PORTFOLIO 261
15.4.5 RECENT DEVELOPMENT 261
15.5 BIOHIT OYJ 262
15.5.1 COMPANY SNAPSHOT 262
15.5.2 REVENUE ANALYSIS 262
15.5.3 COMPANY SHARE ANALYSIS 263
15.5.4 PRODUCT PORTFOLIO 263
15.5.5 RECENT DEVELOPMENT 263
15.6 ACCUBIOTECH CO LTD 264
15.6.1 COMPANY SNAPSHOT 264
15.6.2 PRODUCT PORTFOLIO 264
15.6.3 RECENT DEVELOPMENT 264
15.7 ACCUQUIK TEST KITS 265
15.7.1 COMPANY SNAPSHOT 265
15.7.2 PRODUCT PORTFOLIO 265
15.7.3 RECENT DEVELOPMENT 265
15.8 AIDIAN 266
15.8.1 COMPANY PROFILE 266
15.8.2 PRODUCT PORTFOLIO 266
15.8.3 RECENT DEVELOPMENT 266
15.9 ALFA SCIENTIFIC DESIGNS, INC. 267
15.9.1 COMPANY SNAPSHOT 267
15.9.2 PRODUCT PORTFOLIO 267
15.9.3 RECENT DEVELOPMENT 267
15.10 APACOR LIMITED 268
15.10.1 COMPANY SNAPSHOT 268
15.10.2 PRODUCT PORTFOLIO 268
15.10.3 RECENT DEVELOPMENT 268
15.11 BIOPANDA REAGENTS LTD 269
15.11.1 COMPANY SNAPSHOT 269
15.11.2 PRODUCT PORTFOLIO 269
15.11.3 RECENT DEVELOPMENT 269
15.12 BODITECH MED INC. 270
15.12.1 COMPANY SNAPSHOT 270
15.12.2 PRODUCT PORTFOLIO 270
15.12.3 RECENT DEVELOPMENT 270
15.13 CENOGENICS CORPORATION 271
15.13.1 COMPANY SNAPSHOT 271
15.13.2 PRODUCT PORTFOLIO 271
15.13.3 RECENT DEVELOPMENT 271
15.14 CERTEST BIOTEC. 272
15.14.1 COMPANY SNAPSHOT 272
15.14.2 PRODUCT PORTFOLIO 272
15.14.3 RECENT DEVELOPMENT 272
15.15 CTK BIOTECH, INC. 273
15.15.1 COMPANY SNAPSHOT 273
15.15.2 PRODUCT PORTFOLIO 273
15.15.3 RECENT DEVELOPMENT 273
15.16 EDP BIOTECH 274
15.16.1 COMPANY SNAPSHOT 274
15.16.2 PRODUCT PORTFOLIO 274
15.16.3 1.16.3 RECENT DEVELOPMENT 274
15.17 EPITOPE DIAGNOSTICS, INC. 275
15.17.1 COMPANY SNAPSHOT 275
15.17.2 PRODUCT PORTFOLIO 275
15.17.3 RECENT DEVELOPMENT 275
15.18 EUROLYSER DIAGNOSTICA GMBH 276
15.18.1 COMPANY SNAPSHOT 276
15.18.2 PRODUCT PORTFOLIO 276
15.18.3 RECENT DEVELOPMENT 276
15.19 FIRSTEP 277
15.19.1 COMPANY SNAPSHOT 277
15.19.2 PRODUCT PORTFOLIO 277
15.19.3 RECENT DEVELOPMENT 277
15.20 HANGZHOU CLONGENE BIOTECH CO., LTD 278
15.20.1 COMPANY SNAPSHOT 278
15.20.2 PRODUCT PORTFOLIO 278
15.20.3 RECENT DEVELOPMENT 278

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.